Galderma reported first-half 2026 net sales of $3.134 billion, a 24.6% year-on-year increase at constant currency, and lifted full-year guidance on the strength of the result. The company attributed momentum to Nemluvio (a biostimulator in the CaHA class) and indirect demand from GLP-1 weight-loss drug adoption, which is driving patients into aesthetic practices seeking facial volume restoration and skin quality treatments.
Business & M&A
Galderma Posts Record H1 2026 Sales of $3.134B — Raises Full-Year Guidance
24.6% YoY growth at constant currency driven by Nemluvio strength and GLP-1 weight-loss trend tailwinds.
24.6% YoY growth at constant currency, with Nemluvio and GLP-1 tailwinds driving demand.
For practice owners, the data signals sustained category tailwinds. Galderma's portfolio breadth—spanning neuromodulators, fillers, and biostimulators—positions it to capture multiple revenue streams per patient visit. The GLP-1 phenomenon, while not a Galderma product, is functioning as a patient-acquisition engine for the broader medspa channel.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.